NEW YORK (AP) _ Axovant Sciences Ltd. (SIOX) on Friday reported a loss of $25.5 million in its fiscal third quarter.
NEW YORK (AP) _ Axovant Sciences Ltd. (SIOX) on Friday reported a loss of $21.2 million in its fiscal second quarter.
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform...
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sio Gene Therapies, Inc. (“Sio” or the “Company”) (NASDAQ: AXGT). Such investors...
NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Axovant Gene Therapies Ltd. (“Axovant” or the “Company”) (NASDAQ: AXGT). Such investors...
NEW YORK, Nov. 21, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Axovant Gene Therapies Ltd. (“Axovant” or the “Company”) (NASDAQ: AXGT). Such investors...
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform...
NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Axovant Gene Therapies Ltd. (“Axovant” or the “Company”) (NASDAQ: AXGT). Such investors...
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform...